ZO-Y60 Phase III clinical trial
Phase 3
- Conditions
- Gastrointestinal disease
- Registration Number
- JPRN-jRCT1080221685
- Lead Sponsor
- ZERIA Pharmaceutical Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with gasstrointestinal disease.
Out-patients who signed a written informed consent.
If patient age is under 20 years old, a written informed consent have to be obtained from both participant and his/her parent(s).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ZO-Y60's therapeutic effects in gastrointestinal disease?
How does ZO-Y60 compare to standard-of-care treatments for inflammatory bowel disease in Phase III trials?
Which biomarkers correlate with ZO-Y60 efficacy in ZERIA Pharmaceutical's GI disease studies?
What adverse events are reported in ZO-Y60 trials and how are they managed in clinical practice?
Are there combination therapies or competitor drugs targeting PPAR gamma for GI disorders alongside ZO-Y60?